Advice
in the absence of a submission from the holder of the marketing authorisation:
azilsartan medoxomil (Edarbi®) is not recommended for use within NHS Scotland.
Indication under review: treatment of essential hypertension in adults.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice77KB (PDF)
Medicine details
- Medicine name:
- azilsartan medoxomil (Edarbi)
- SMC ID:
- 803/12
- Indication:
- Treatment of essential hypertension in adults.
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 July 2012